AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39356138
Drug: Panitumumab (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4)
Trial: 39356537
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) - loading dose of 10 mg/kg followed by maintenance infusion of 5 mg/kg per hour during surgery
Trial: 39356943
Drug: Superior rectal
RxNorm normalized name: Sus scrofa superior gastric plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superior rectal artery embolization
Trial: 39356946
Drug: Percutaneous Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous Ethanol Injection
Trial: 39357673
Drug: Beans (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beans (120 g, ∼0.75 cups)
Trial: 39357673
Drug: Peas (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peas (120 g, ∼0.75 cups)
Trial: 39358355
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg davunetide/daily
Trial: 39358355
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg davunetide/twice-daily
Trial: 39358661
Drug: Selvigaltin (GB1211)
RxNorm normalized name: GB1211
DrugBank: GB1211 (DB17499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selvigaltin (GB1211) 100 mg oral
Trial: 39358806
Drug: Exenatide (EQW)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide (EQW) 2 mg once weekly
Trial: 39359014
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy for STEMI
Trial: 39359872
Drug: Physical facial
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physical facial nerve rehabilitation (PFNR) therapy alone (neuromuscular retraining and Kabat proprioceptive neuromuscular facilitation)
Trial: 39360368
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,200 mg/day orally
Trial: 39361946
Drug: Standard-of-care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care chemotherapy (SOC) - once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin
Trial: 39362046
Drug: Denileukin diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Denileukin diftitox (ONTAK) at 5 μg/kg
Trial: 39362046
Drug: Denileukin diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Denileukin diftitox (ONTAK) at 15 μg/kg
Trial: 39362046
Drug: Denileukin diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Denileukin diftitox (ONTAK) at 25 μg/kg
Trial: 39362248
Drug: Ziftomenib (50-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziftomenib (50-1000 mg) orally once daily in 28-day cycles (Phase 1a)
Trial: 39362248
Drug: Ziftomenib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziftomenib (600 mg) in Phase 1b
Trial: 39362248
Drug: Ziftomenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziftomenib (200 mg) in Phase 1b
Trial: 39362249
Drug: Capmatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capmatinib (400 mg orally twice daily)
Trial: 39362907
Drug: Manual lymphatic
RxNorm normalized name: PINPOINT Lymphatics Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymphatic drainage (MLD) administered from 180 to 195 minutes
Trial: 39363095
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus testosterone
Trial: 39363100
Drug: Doxycycline post-exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline post-exposure prophylaxis (200-mg dose taken after condomless sex)
Trial: 39363320
Drug: Tailored treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored treatment based on resistance mechanism
Trial: 39363801
Drug: Allergen Immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen Immunotherapy (AIT)
Trial: 39363801
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AIT and biologics
Trial: 39364940
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) therapy
Trial: 39365957
Drug: FDG-PET-guided adaptive
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG-PET-guided adaptive treatment (mean 71 Gy in 30 fractions, mean lung dose 17.9 Gy)
Trial: 39365957
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (60 Gy/30 fractions)
Trial: 39365960
Drug: Glofitamab monotherapy
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab monotherapy with obinutuzumab pretreatment (Gpt) 1,000 or 2,000 mg 7 days before glofitamab; glofitamab step-up dosing on days 8 (2.5 mg) and 15 (10 mg) of cycle 1, target dose of 16 or 30 mg once every 3 weeks from cycle 2 day 1 onward, for 12 cycles.
Trial: 39365992
Drug: Ruxolitinib 10mg
RxNorm normalized name: RUXOLITINIB 10MG ORAL TAB
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 10mg twice daily for up to 12 cycles
Trial: 39366653
Drug: Bilateral sphenopalatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sphenopalatine ganglion block (SPGB) with 5 mL lidocaine 2% on each side (G1)
Trial: 39366653
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia and bilateral saline injection of 5 mL on each side (G2)
Trial: 39366722
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (MTX) initiated and increased to maximum tolerated dose by week 12
Trial: 39366722
Drug: Continued MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued MTX dose with subcutaneous adalimumab
Trial: 39366751
Drug: Niraparib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib monotherapy
Trial: 39366752
Drug: HBM4003 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 weeks
Trial: 39367366
Drug: ASSIP (Attempted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASSIP (Attempted Suicide Short Intervention Program) plus treatment as usual
Trial: 39367439
Drug: Telehealth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth intervention using videoconferencing technology for linking incarcerated women to community MOUD treatment.
Trial: 39367749
Drug: Impulse oscillometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impulse oscillometry for evaluating SAD, defined as R5-R20 ⩾0.07 kPa/L/s.
Trial: 39368130
Drug: Pediatric COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric COVID-19 vaccine uptake influenced by concerns and misinformation surrounding the new vaccine.
Trial: 39368130
Drug: Pediatric COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric COVID-19 vaccine uptake influenced by witnessing others' vaccine and pandemic experiences.
Trial: 39368130
Drug: Pediatric COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric COVID-19 vaccine uptake influenced by participation in social activities.
Trial: 39368130
Drug: Pediatric COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric COVID-19 vaccine uptake influenced by the politicization of and political climate surrounding the vaccine.
Trial: 39368130
Drug: Pediatric COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric COVID-19 vaccine uptake influenced by health education surrounding the vaccines.
Trial: 39368870
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) app
Trial: 39368871
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) self-help app
Trial: 39369129
Drug: Time-to-therapy >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-to-therapy > 2 years
Trial: 39369129
Drug: Time-to-therapy >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-to-therapy > 2 years in low-risk subgroup
Trial: 39369239
Drug: Five-session telephone-delivered
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-session telephone-delivered behavioural activation treatment as an add-on to treatment as usual
Trial: 39369239
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual in primary care
Trial: 39369249
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction
Trial: 39370144
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
RxNorm normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for 48 weeks
Trial: 39371161
Drug: Comparison to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison to previous solutions trained with ground truth acoustic voice recordings
Trial: 39371165
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g daily of KE (bis-octanoyl (R)-1,3-butanediol)
Trial: 39372262
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin D (cholecalciferol 50 mcg)
Trial: 39372369
Drug: KETO diet
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KETO diet (carbohydrate restriction-induced LDL-C ≥190 mg/dL)
Trial: 39373173
Drug: FIT threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT threshold of 15 μg/g
Trial: 39373173
Drug: FIT threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT threshold of 47 μg/g
Trial: 39373173
Drug: FIT threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT threshold of 150 μg/g
Trial: 39373311
Drug: BI 1820237
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1820237 (0.075-2.4 mg)
Trial: 39373311
Drug: BI 1820237
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1820237 (1.2 mg)
Trial: 39373311
Drug: BI 1820237
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1820237 (0.025-1.2 mg) + liraglutide (0.6 mg)
Trial: 39373498
Drug: Post-natal antibiotic
RxNorm normalized name: B-Natal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-natal antibiotic exposure
Trial: 39373498
Drug: Antibiotic-naive infants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-naive infants
Trial: 39373498
Drug: Overall presence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall presence of antibiotic resistance genes (ARGs)
Trial: 39373498
Drug: Preterm infants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterm infants without direct or intrapartum antibiotic exposure
Trial: 39373831
Drug: Hello Bundle
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hello Bundle intervention (6 components: Hello campaign posters, email reminders, integrating greetings in morning huddles, hello jars, lead-by-example initiatives, daily updated hello board)
Trial: 39373843
Drug: STS101 (5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STS101 (5.2 mg dihydroergotamine nasal powder)
Trial: 39373844
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER (extended-release capsules) at doses between 200 and 600 mg/day
Trial: 39373844
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER (extended-release capsules) at doses ≥ 400 mg/day
Trial: 39373844
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER (extended-release capsules)
Trial: 39374004
Drug: Masked taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masked taper plus cognitive behavioral therapy-augmented program (MTcap)
Trial: 39374004
Drug: Standard CBTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CBTI plus supervised (unmasked) gradual taper (SGT)
Trial: 39374216
Drug: Neck-specific exercise
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck-specific exercise (NSE) supervised by a physiotherapist twice a week for 12 weeks
Trial: 39374480
Drug: Matched targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched targeted therapies (MTTs) post-MTB evaluation
Trial: 39374480
Drug: Approved tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approved tyrosine kinase inhibitors
Trial: 39374480
Drug: Standard chemotherapy/immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy/immunotherapy
Trial: 39374480
Drug: No matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No matched targeted therapy (MTT)
Trial: 39374521
Drug: Asciminib 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib 80 mg daily plus dasatinib 140 mg daily plus prednisone 60 mg/m2 daily
Trial: 39374532
Drug: Pitavastatin, 4
RxNorm normalized name: Pitavastatin, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin, 4 mg daily
Trial: 39374555
Drug: Brief Mindfulness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Mindfulness Intervention (Brief MI) - 15-minute audio mindfulness practice daily from embryo transfer to pregnancy test (total 180-210 minutes)
Trial: 39374555
Drug: Extremely Brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extremely Brief Meditation (EBMI) - Weekly 40-minute sessions with a meditator instructor (total 80 minutes)
Trial: 39374605
Drug: Booster group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster group (received homologous booster dose at month 18)
Trial: 39374638
Drug: Early 3-month
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early 3-month direct oral anticoagulant (DOAC) therapy followed by single antiplatelet therapy (experimental arm)
Trial: 39374638
Drug: Lifelong single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifelong single antiplatelet therapy (standard arm)
Trial: 39374788
Drug: Composite intravenous
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite intravenous lipid emulsion (CO-ILE) with fish oil
Trial: 39375168
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with avutometinib plus defactinib
Trial: 39375168
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of treatment
Trial: 39375179
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (400 mcg) and vitamin B supplementation for 3 months
Trial: 39375634
Drug: Vestibular socket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular socket therapy (VST) in infected sockets (group I)
Trial: 39375634
Drug: Vestibular socket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular socket therapy (VST) in non-infected sockets (group N)
Trial: 39375710
Drug: Standard SafeCare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard SafeCare (active treatment control); n=25
Trial: 39375869
Drug: Dapagliflozin/linagliptin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin/linagliptin fixed-dose combination (FDC [AJU-A51]) 10/5 mg/day (n=117)
Trial: 39375869
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg plus placebo (n=118)
Trial: 39375952
Drug: ABL001/CTX-009 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABL001/CTX-009 (10 mg/kg every other week)
Trial: 39375952
Drug: ABL001/CTX-009 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABL001/CTX-009 (15 mg/kg every three weeks)
Trial: 39375952
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing
Trial: 39376152
Drug: LEAP! Rx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEAP! Rx (exercise and monthly brain health education)
Trial: 39376771
Drug: Lidocaine 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2.0% infusion
Trial: 39376771
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% infusion
Trial: 39376791
Drug: Hypotonic fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic fluids (NaCl <130 mmol/L)
Trial: 39376791
Drug: Isotonic fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic fluids (NaCl = 130-154 mmol/L)
Trial: 39376864
Drug: Ethos OART
RxNorm normalized name: isostearyl ethylimidazolinium ethosulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethos OART platform delivering multi-site pulsed hypofractionated radiotherapy (40 Gy in 5 fractions) in combination with standard of care (SOC) chemoimmunotherapy.
Trial: 39377148
Drug: Crushed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed ticagrelor administered via nasogastric tube
Trial: 39377970
Drug: no redifferentiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no redifferentiation therapy
Trial: 39378042
Drug: Tegoprazan 50
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 50 mg once daily
Trial: 39378079
Drug: Ophthalmic acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic acupuncture with 'De Qi' sensation
Trial: 39378080
Drug: Adaptive messaging
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive messaging group receiving text messages selected by a reinforcement learning algorithm daily
Trial: 39378080
Drug: Random messaging
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random messaging group receiving randomly selected feedback and motivational text messages daily
Trial: 39378080
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving a weekly mood monitoring message
Trial: 39378281
Drug: 4-week loading
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week loading dose of 300 mg clofazimine once daily
Trial: 39378281
Drug: 6-week loading
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week loading dose regimen
Trial: 39378326
Drug: IM20×3 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM20×3 group (3 standard doses of 20 μg at 0-1-6 months)
Trial: 39378326
Drug: IM20×4 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM20×4 group (4 standard doses of 20 μg at 0-1-2-6 months)
Trial: 39378326
Drug: IM60×4 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM60×4 group (4 triple doses of 60 μg at 0-1-2-6 months)
Trial: 39378423
Drug: Innovative technologies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovative technologies and treatment pathways
Trial: 39379403
Drug: Viltolarsen 80
RxNorm normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Viltolarsen 80 mg/kg intravenous once weekly for 48 weeks
Trial: 39379540
Drug: Peroral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral antibiotics (3-day course)
Trial: 39379672
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mFRI and urinary injury biomarkers (uNAG or uNGAL)